Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Colorectal Neoplasms 4Breast Neoplasms 3Urogenital Neoplasms 2Stomach Neoplasms 2Sarcoma 2Ovarian Neoplasms 2Melanoma 2Lung Neoplasms 2Liver Neoplasms 2Head and Neck Neoplasms 2Neoplasm Metastasis 1Inflammation 1Fatigue 1Cognitive Dysfunction 1Brain Neoplasms 1Behavior 1

Interventions

Nivolumab 146Ipilimumab 137pembrolizumab 122Cyclophosphamide 78Interleukin-2 69aldesleukin 63Temozolomide 46trametinib 37Radiosurgery 37Vemurafenib 36fludarabine 34Biopsy 34dabrafenib 33Radiotherapy 33Blood Specimen Collection 31fludarabine phosphate 30sargramostim 27Bevacizumab 27Introns 23Dacarbazine 22Magnetic Resonance Spectroscopy 21Specimen Handling 20CTLA-4 Antigen 20encorafenib 19cobimetinib 19binimetinib 19Paclitaxel 19Granulocyte-Macrophage Colony-Stimulating Factor 19Cisplatin 17incomplete Freund's adjuvant 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Melanoma × Riluzole × Clear all
NCT00866840 2024-01-19

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Rutgers, The State University of New Jersey

Phase 2 Completed
13 enrolled 11 charts
Dermatologic

Melanoma

NCT00667901 2009-12-11

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

Rutgers, The State University of New Jersey

Phase 1 Terminated
15 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡